Weizhi Wang

3.9k citations
69 papers · 2.3k indexed · 1 hit paper · h-index 28
Topics
Cancer-related molecular mechanisms research (15 papers)MicroRNA in disease regulation (14 papers)Gastric Cancer Management and Outcomes (12 papers)

In The Last Decade

Weizhi Wang

66 papers receiving 2.3k citations

Hit Papers

Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin...20192026202120232019100200300

Peers

Weizhi Wang
Comparison fields: 5 of 115
  • Molecular Biology 1.6k
  • Cancer Research 1.3k
  • Pulmonary and Respiratory Medicine 308
  • Surgery 281
  • Oncology 255
Replace Kshama Mehta with:
Kshama Mehta United States
Katsutoshi Shoda Japan
Georgia Levidou Greece
Jun Song China
Béatrice Parfait France
Sandra Cascio United States
Hongwei Zhang China
Xiaojun Wu China
Makoto Ishikawa Japan
Weizhi Wang relative to Kshama Mehta United States Kshama Mehta's profile →
Citations per field
00.5×3.5×
Kshama Mehta · 1×
Citations per year

Countries citing papers authored by Weizhi Wang

Since Specialization
Citations

This map shows the geographic impact of Weizhi Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weizhi Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weizhi Wang more than expected).

Fields of papers citing papers by Weizhi Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weizhi Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weizhi Wang. The network helps show where Weizhi Wang may publish in the future.

Co-authorship network of co-authors of Weizhi Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Weizhi Wang. A scholar is included among the top collaborators of Weizhi Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weizhi Wang. Weizhi Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 20
3 58
4 2
5 48
6 6
7 8
8 36
9 26
10 19
11 6
12 1
13 66
14 19
15 36
16 9
17 14
18 63
19 51
20 8

About Weizhi Wang

Weizhi Wang is a scholar working on Cancer Research, Gastroenterology and Molecular Biology, having authored 69 papers that have together received 2.3k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (15 papers), MicroRNA in disease regulation (14 papers) and Gastric Cancer Management and Outcomes (12 papers). The work is most often cited by research in Cancer Research (1.3k citations), Molecular Biology (1.6k citations) and Gastroenterology (113 citations). Weizhi Wang has collaborated with scholars based in China, United States and South Korea. Frequent co-authors include Zekuan Xu, Hao Xu, Bowen Li, Xiaofei Zhi, Linjun Wang, Zhongyuan He, Guangli Sun, Jie Tang, Sen Wang and Lu Wang. Their work appears in journals such as Blood, Gastroenterology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026